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Abstract
The Ubiquitin-Specific Protease 22 (USP22) is a deubiquitinating subunit of the mammalian SAGA transcriptional co-
activating complex. USP22 was identified as a member of the so-called “death-from-cancer” signature predicting therapy
failure in cancer patients. However, the importance and functional role of USP22 in different types and subtypes of cancer
remain largely unknown. In the present study, we leveraged human cell lines and genetic mouse models to investigate the
role of USP22 in HER2-driven breast cancer (HER2+-BC) and demonstrate for the first time that USP22 is required for
the tumorigenic properties in murine and human HER2+-BC models. To get insight into the underlying mechanisms,
we performed transcriptome-wide gene expression analyses and identified the Unfolded Protein Response (UPR) as a
pathway deregulated upon USP22 loss. The UPR is normally induced upon extrinsic or intrinsic stresses that can promote
cell survival and recovery if shortly activated or programmed cell death if activated for an extended period. Strikingly, we
found that USP22 actively suppresses UPR induction in HER2+-BC cells by stabilizing the major endoplasmic reticulum
(ER) chaperone HSPA5. Consistently, loss of USP22 renders tumor cells more sensitive to apoptosis and significantly
increases the efficiency of therapies targeting the ER folding capacity. Together, our data suggest that therapeutic
strategies targeting USP22 activity may sensitize tumor cells to UPR induction and could provide a novel, effective
approach to treat HER2+-BC.
Introduction
HER2-positive breast cancer (HER2+-BC) is character-
ized by the overexpression and/or amplification of the
ERBB2 gene encoding the epidermal growth factor
receptor 2, which occurs in ≈15–20% of all breast cancers
(BC) [1, 2]. Abnormally high levels of HER2 at the
plasma membrane of breast epithelial cells promote sus-
tained intracellular signaling and stimulate aberrant cell
division and tumor formation. The emergence of ther-
apeutic strategies specifically targeting the HER2 receptor
and its downstream signaling two decades ago dramati-
cally improved the prognosis of HER2+-BC patients
[3, 4]. Despite this progress, numerous patients do not
respond to the therapy or develop resistant recurrences,
and ultimately succumb to the disease [5]. Thus, a better
understanding of the specific molecular dependencies of
HER2+-BC may uncover novel therapeutic targets that
have the potential to enhance the efficacy of existing
therapies or provide alternative treatment approaches for
this aggressive disease.
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The Ubiquitin Specific Peptidase 22 (USP22) is a
deubiquitinating enzyme that was identified as a member
of an 11 gene “death-from-cancer” signature which
correlates with cancer stem cell characteristics and pre-
dicts disease recurrence, metastasis, and poor response to
therapy in malignancies of various origins including BC
[6]. USP22 is a conserved subunit of the deubiquitination
module (DUBm) of the Spt-Ada-Gcn5 acetyltransferase
(SAGA) complex, a large multimeric complex that plays
an important role in gene regulation [7, 8]. Specifically,
USP22 is the catalytic subunit of the SAGA DUBm and
functions to modulate gene transcription via removal of
monoubiquitination from histones H2A and H2B [9].
Noteworthy, USP22 also modulates the stability and
function of multiple non-histone targets associated with
cancer progression and poor prognostic outcome
including c-Myc, Cyclin D1, Cyclin B1, EGFR, SOS,
SIRT1, COX2, XPC, KDM1A, ERa, SHH [10–19], as
well as nodal immunologic factors [20–22]. Our previous
studies demonstrated a function for USP22 in intestine
epithelial cell differentiation in vivo and a surprising
tumor-suppressive function for USP22 in colorectal
cancer [23, 24]. Importantly, while loss of USP22
potentiated colorectal tumorigenesis via activation of the
mTOR pathway, USP22-deficient tumors also displayed
a particular vulnerability to either mTOR or HSP90
inhibitors [24, 25]. Together, these studies suggest an
ambiguous and context-dependent role of USP22 where
it can have either tumor supportive or tumor-suppressive
functions.
The Unfolded Protein Response (UPR) pathway has
been shown to play a decisive role in HER2+-BC
aggressiveness [26]. Aberrant activation of oncogenes
including HER2 results in increased protein synthesis
[27]. The consequent induction of endoplasmic reticulum
(ER) stress due to the abnormal accumulation of mis-
folded proteins leads to the activation of the three sig-
naling branches of the UPR controlled by PERK, IRE1α,
and ATF6, respectively. Although low UPR activation has
been shown to support the oncogenic transformation and
tumor progression, higher and prolonged UPR signaling
levels elicit a switch to anti-tumor, p53-independent pro-
apoptotic signaling [27]. Consequently, sustained UPR
activation is associated with better outcomes in HER2+-BC
[26, 28–30].
In this study, we utilized both in vitro cell culture and
an in vivo genetic mouse model and identified the ER-
chaperone HSPA5 (also known as GRP78 or BiP) as a
previously unknown and important deubiquitination client
of USP22. This mechanism is required for the tumorigenic
properties of HER2+-BC cells whereby USP22 inhibits
UPR signaling and suppresses PERK-mediated pro-
grammed cell death via stabilization of HSPA5.
Results
USP22 supports HER2-driven mammary
carcinogenesis in vivo
A positive correlation between USP22 expression and
cancer disease progression has been frequently reported in
the past. Indeed, analysis of HER2+-BC patients within the
TCGA breast cancer cohort confirms that patients with
tumors displaying high USP22 expression show a parti-
cularly poor prognosis (Fig. 1A). However, to date, in vivo
genetic mouse model studies examining the role of USP22
in cancer have been limited to prostate, leukemia, and
colorectal malignancies [16, 25, 31]. To investigate the
consequences of Usp22 loss in HER2-driven mammary
carcinomas, we utilized a transgenic mouse model in which
the gene encoding HER2 (Erbb2) was expressed under the
mammary-specific MMTV promoter (MMTV-Erbb2). The
additional mammary-specific deletion of Usp22 was
achieved by crossing a mouse line containing a floxed
Usp22 allele (Usp22flox) with the mammary-specific
deletion line MMTV-Cre (Fig. 1B) [25]. Subsequent
monitoring of tumor occurrence revealed a strong increase
of disease-free survival in animals with tissue-specific
Usp22 knockout (median survival: 335 days) compared
to Usp22wt/wt animals (median survival: 166 days, see
Fig. 1C). Remarkably, 12.5% of Usp22fl/fl mice never
developed the disease, pointing at a critical role of Usp22
in HER2-driven BC. Interestingly, heterozygous Usp22
deletion in mammary carcinoma cells was sufficient to
significantly increase disease-free survival of MMTV-
Erbb2 animals (median survival: 209 days), implying that
the reduction of USP22 levels is sufficient to impair the
oncogenic properties of HER2+-BC. Further analyses
demonstrated that Usp22 loss not only delayed tumor
growth but also strongly reduced tumor burden as reflected
by the decreased number of tumors per animal and slower
tumor growth kinetics (Fig. 1D, E). We confirmed the
efficiency of the knockout in Usp22fl/fl tumors via qRT-
PCR (Fig. 1F). Interestingly, neither the morphology nor
the H2B-monoubiquitination (H2Bub1) levels of the
growing tumors were affected by Usp22 deletion. Addi-
tionally, immunohistochemical analyses confirmed that the
expression of HER2, the driving oncogene in this tumor
model, was not affected by Usp22 deletion (Fig. 1G). Our
findings, therefore, demonstrate a critical tumor-promoting
role of USP22 in HER2-driven BC.
USP22 loss impairs the oncogenic properties of
HER2+-BC cells in vitro
To extend our observations to the human disease, we uti-
lized two HER2+ human BC cell lines (HCC1954 and
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SKBR3) and first investigated the effect of USP22 depletion
on their oncogenic properties. Loss of USP22 (Fig. 2A, B)
led to a pronounced reduction of cell number, clonogenic
growth, and migratory properties of both cell lines
(Fig. 2C–E). To evaluate whether the loss of USP22 affects
the HER2-signaling cascade, we examined the phosphor-
ylation of ERK1/2 and AKT, two major downstream
molecular targets of HER2 following USP22 depletion [27].
Notably, in contrast to treatment with the HER2 inhibitor
lapatinib, which led to a prominent reduction of both
pERK1/2 and pAKT, we did not observe notable changes in
the signal transduction downstream of HER2 following
USP22 depletion in HCC1954 (Fig. 2F) and SKBR3 cells
(Fig. S1A). Consistent with the observed effect on pro-
liferation, the PCNA expression was strongly reduced upon
USP22 silencing in HCC1954 cells compared to control
transfected cells (Fig. 2G). Taken together, loss of USP22
interferes with the tumorigenicity of HER2+-BC cells
in vitro and in vivo without affecting HER2 expression or
its canonical downstream signaling cascade.
Fig. 1 USP22 loss decreases the incidence and aggressiveness
of HER2+-BC in the MMTV-Erbb2 genetic mouse model. A
Progression-free interval (PFI), relapse-free survival (RFS), and distant
metastasis-free survival (DMFS) plot of low- and high-USP22
expressing HER2+-BC patients. Survival data were retrieved from
TCGA-BRCA (xenabrowser.net) and KM-plotter. Log-rank test. Used
parameters are provided in Supplementary Material and Methods.
B Schematic representation of the three transgenes of the MMTV-
Erbb2; MMTV-cre; Usp22flox mouse model. C Disease-free survival
analysis of Usp22wt/wt (n= 28); Usp22fl/wt (n= 17) and Usp22fl/fl (n=
16) animals. Log-rank test. D Average number of tumors per animals
in Usp22wt/wt (n= 29); Usp22fl/wt (n= 18) and Usp22fl/fl (n= 16)
animals. One-way Anova test. E Tumor growth kinetics of Usp22wt/wt
(n= 22) and Usp22fl/fl (n= 11) tumors. Student t-test on the area under
the curve (AUC). F Validation of Usp22 deletion efficiency in
Usp22wt/wt, Usp22fl/wt and Usp22fl/fl tumors (n= 5 per group) via RT-
qPCR. One-way ANOVA test. G Representative H&E, HER2, and
H2Bub1 staining on Usp22wt/wt and Usp22fl/fl tumors section. Black
scale bar: 50 μm. White scale bar: 25 μm. ** p val < 0.01, *** p val <
0.005. Error bars: standard error of the mean (SEM).
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USP22 loss triggers apoptosis in HER2+-BC cells
To understand the USP22-dependent signaling pathways
underlying its oncogenic properties, we performed
transcriptome-wide analyses in murine HER2+-BC tumors
and HCC1954 cells by mRNA-sequencing (mRNA-seq)
following genetic Usp22 deletion or siRNA-mediated
USP22 depletion, respectively. We identified 1141 differ-
entially regulated genes upon Usp22 loss in the murine
tumors, and 496 differentially regulated genes upon USP22
knockdown in HCC1954 cells (Fig. 3A). Interestingly, the
overlap of genes regulated in murine and human tumor cells
was rather low (Fig. S1B and C). However, as USP22
governs similar oncogenic features in both in vitro and
in vivo systems, we hypothesized that, despite the scarce
overlap of regulated genes, the underlying molecular
mechanisms are likely the same in both human and murine
tumors. We, therefore, investigated commonly regulated
pathways in the USP22-deficient condition by using Gene
Set Enrichment Analysis (GSEA) and subsequently inter-
secting the in vitro and in vivo results. We observed that the
majority of significantly enriched gene sets (FDR < 0.25)
upon impairment of USP22 in HCC1954 and HER2-driven
murine tumors substantially overlapped (Fig. 3B). Inter-
estingly, HER2+-BC tumor cells lacking USP22 showed
enrichment for gene signatures associated with stress-
induced signaling pathways (e.g., hypoxia, p53 pathway)
and apoptosis (Fig. 3B, C). To assess whether USP22 loss
Fig. 2 USP22 loss impairs oncogenic properties of HER2+-BC cells
in vitro. A–B Validation of USP22 knockdown efficiency via qRT-
PCR (A) and western blot analysis (B) in HCC1954 and SKBR3 cells.
C–D Representative crystal violet staining (left panels) and quantifi-
cations (right panels) of cell confluency (C) and colony formation
assay (D) of siControl- and siUSP22-treated HCC1954 and SKBR3
cells. E Trans-well migration assay of HCC1954 cells with or without
USP22 knockdown. Left panel: representative crystal violet; right
panel: quantification. F Western blot analyses showing no loss of
pAKT and pERK upon USP22 silencing. Lapatinib was used as a
positive control (lap; 1 μΜ, 12 h treatment). G Representative pictures
of PCNA and DAPI immunofluorescence staining in siUSP22- and
siControl-treated HCC1954 cells. Quantification of average PCNA
intensity is provided in the right panel (n= 5 pictures per replicate).
All experiments were performed in biological triplicates. Error bars:
standard error of the mean (SEM). Statistical analyses: A, C, D, and
E: Student t-test (for the growth kinetic assays, the area under the
curve was used to calculate the statistic difference); G: Mann–Whitney
test. *p < 0.05, ***p val < 0.005.
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indeed induces apoptosis in HER2+-BC cells, we first
examined cell morphology following USP22 knockdown
and observed an increase of membrane blebbing and cyto-
plasmic vacuolization, characteristics of programmed cell
death [32] (Fig. 3D). The induction of apoptosis was further
confirmed by assessing the levels of cleaved PARP as well
as through flow cytometry-based annexin V assay (Fig. 3E,
F). In agreement, the levels of the apoptosis inducer Cas-
pase 3 (Casp3) as well as its active cleaved form were
elevated in Usp22fl/fl mammary carcinomas measured by
RT-qPCR and IHC staining (Fig. 3G–I). Finally, we rea-
soned that if a higher rate of apoptosis is responsible for the
reduced tumorigenic properties observed upon USP22 loss
in HER2+-BC, the inhibition of caspase activity should, at
least partially, rescue the impaired phenotype. Strikingly,
treatment with the pan-caspase inhibitor Z-VAD almost
fully restored cellular viability of USP22-deficient
HCC1954 cells (Fig. 3J). Together, for the first time,
these findings demonstrate that USP22 loss triggers apop-
tosis induction in HER2+-BC cells in vivo and in vitro.
Fig. 3 Impaired USP22 expression sensitizes HER2+-BC cells to
apoptosis. A Volcano plots showing differentially regulated genes in
Usp22fl/fl (n= 4) versus Usp22wt/wt (n= 4) tumors (left panel) and in
HCC1954 cells treated with siUSP22 (n= 3) versus siControl (n= 2)
(right panel). B Venn diagram showing gene sets of the MSigDB
“HALLMARK” gene sets collection commonly enriched upon USP22
loss in murine HER2+-mammary carcinomas and human HCC1954
cells. C GSEA profiles: both mouse and human HER2+-tumor cells
significantly enrich the “HALLMARK_APOPTOSIS” gene signature
upon USP22 loss. D–F HCC1954 cells strongly induce apoptosis upon
USP22-knockdown, as shown in representative phase-contrast pictures
(D), western blot analysis of cleaved PARP (E), and FACS-based
Annexin V assay (F). G Measurement of Casp3 levels via RT-qPCR
in Usp22wt/wt and Usp22fl/fl tumors (n= 5 tumors per group).
H–I Immunohistochemical staining of full (H) and cleaved (I) caspase
3 in Usp22wt/wt- and Usp22fl/fl-tumors. Black scale bar= 50 µm.
J Proliferation assay of siControl- and siUSP22-treated HCC1954
cells, co-treated with Z-VAD (80 μΜ). Statistical analyses: Student
t-test (F, G, and J): *p val < 0.05, ***p val < 0.005. All experiments
were performed in biological triplicates or more (specified where
applicable). Error bars: standard error of the mean (SEM). NES Nor-
malized Enrichment Score.
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USP22 loss increases the sensitivity of HER2+-BC to
the unfolded protein response
To elucidate the molecular mechanisms underlying
increased apoptosis in USP22-deficient HER2+-BC cells,
we focused on the genes of the “HALLMARK_A-
POPTOSIS” signature that were commonly upregulated
in vitro and in vivo. As a highly ranked gene in both HER2
+-BC systems, the pro-apoptotic Activating Transcription
Factor 3 (ATF3) gene particularly drew our attention
(Fig. 4A, Fig. S2A–B). The increased mRNA levels of
ATF3 and another pro-apoptotic factor BCL10, another
member of the same signature, were validated via qRT-PCR
in the HER2-driven murine tumors and HCC1954 cells
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(Fig. 4B). Accordingly, IHC staining revealed pronounced
increased levels of ATF3 in Usp22fl/fl tumors compared to
their wild-type counterpart (Fig. 4C). To determine whether
elevated ATF3 levels underlie the transcriptional changes
mediated by USP22 loss, we evaluated the “regulatory
target gene sets” MSigDB collection. Indeed, a significant
enrichment of upregulated genes harboring at least one
ATF3 binding site in their promoter was observed in both
siUSP22 and Usp22fl/fl tumor cells (Fig. 4D). Of note, ATF3
also belongs to the previously identified significantly
upregulated genes of the “HALLMARK_HYPOXIA” sig-
nature enriched in both HER2+-BC models (Fig. 3B,
Fig. S2B). ATF3 is a well-known transcription factor fre-
quently activated upon various cellular stress conditions
including hypoxia and endoplasmic reticulum (ER) stress
caused by calcium imbalance, oxidizing environment, or
impaired protein chaperoning capacity [33–35]. To identify
the processes underlying ATF3 stimulation upon USP22
loss, we performed further mining of the GSEA results
obtained from the MSigDB “gene ontology” collection. The
enrichment of numerous signatures characteristic for UPR-
signaling particularly drew our attention. Interestingly, the
“GO_PERK_MEDIATED_UNFOLDED_PROTEIN_RES-
PONSE” gene signature was significantly regulated in both
in vivo and in vitro HER2+-BC models upon USP22 loss
(Fig. 4E, Fig. S2C). Therefore, we hypothesized that the
increased ATF3 expression levels upon USP22 reduction
result from sustained ER stress.
The activation of the UPR-signaling is mediated by three
major transmembrane receptors in the ER-membrane with
stress-sensing functions, IRE1α, PERK, and ATF6α [27].
Upon activation, the serine/threonine kinase PERK cata-
lyzes the phosphorylation of the eukaryotic initiation factor
2 alpha (eIF2a), thereby temporarily impeding the global
protein synthesis and promoting the cap-independent
translation of, among others, Activating Transcription
Factor 4 (ATF4) that in turn stimulates ATF3 transcription.
This cascade of events has been shown to promote cellular
recovery in adverse intra- or extracellular conditions [33].
However, sustained activation of the PERK/ATF4/ATF3
axis of the UPR can stimulate the expression of a panel of
pro-apoptotic genes including CHOP (alias DDIT3),
PMAIP, and GADD34 (alias PPP1R15A) that subsequently
lead to the induction of an efficient p53-independent pro-
grammed cell death if cellular stress becomes irreparable
[36–38]. To test if the higher levels of ATF3 and the
impaired tumor phenotype upon loss of USP22 in HER2
+-BC are caused by sustained activation of the UPR, we
analyzed several known markers and genes regulated by
this pathway. Strikingly, levels of phosphorylated eIF2a (p-
eIF2a) and ATF4 were elevated in siUSP22-treated
HCC1954 cells (Fig. 4F). In vivo, ATF4 protein levels
were also markedly increased in Usp22fl/fl tumors compared
to the wild-type tumors (Fig. 4G). In addition, many UPR-
and ATF3-responsive genes including PPP1R15A, DDIT3,
PPP2R5B, CREB5, CDKN2B, and KLF13 were found to be
upregulated in siUSP22-treated HCC1954 cells (Fig. S2D).
In agreement, GSEA of human HER2+-BC whole tran-
scriptome datasets (TCGA BRCA dataset) demonstrated
that USP22low lesions also have elevated UPR-signaling
compared to USP22high tumors (Fig. 4H). Accordingly, a
significant negative correlation between USP22 expression
and several UPR-responsive genes including ATF3,
PPP1R15A, DDIT3, and BCL2L1 was observed in HER2
+-BC patients (Fig. S2E). Furthermore, higher expression
levels of ATF3, PPP1R15A, PPP2R5B, DDIT3, and BCL10
are associated with better prognosis in HER2+-BC patients,
suggesting an overall tumor-suppressive role of the UPR-
driven signaling cascade (Fig. S2F). Interestingly, the reg-
ulation of UPR by USP22 might not be limited to the HER2
+-BC subtype, as an enrichment of UPR-specific gene
signatures was also observed in mRNA-seq datasets of
normal immortalized mammary epithelial cells (MCF10A)
and prostate carcinoma cells (LNCaP) upon USP22
knockdown (Fig. S3A-B). Taken together, our results sup-
port a negative regulatory role of USP22 in controlling UPR
signaling.
Fig. 4 USP22 loss increases the sensitivity of HER2+-BC to the
unfolded protein response. A Venn diagram of co-regulated genes of
the MSigDB “HALLMARK_APOPTOSIS” in both murine and
human HER2+-BC models. B RT-qPCR validation of the increased
ATF3 and BCL10 expression levels in Usp22fl/fl tumors (n= 5 tumors
per group) and siUSP22-treated HCC1954 cells compared to the
respective control conditions. C Representative pictures of immuno-
histochemical detection of ATF3 levels in Usp22wt/wt and Usp22fl/fl
tumors. Scale bar: 50 μm. D Gene set enrichment analysis in murine
tumor cells and HCC1954 cell line showing enrichment for genes
harboring at least one ATF3 binding site in their regulatory region
(“ATF3_Q6”) upon USP22 loss. E Graphical integration of the GSEA
analysis results from HCC1954 and MMTV-Erbb2 tumor cells upon
USP22 loss utilizing the MSigDB “GO gene sets” collection.
F Western blot analysis showing an increase of p-eIF2a and ATF4
protein levels upon siUSP22-treatment in HCC1954. G Representative
pictures of immunohistochemical detection of ATF4 in Usp22wt/wt and
Usp22fl/fl tumors. Scale bar: 50 μm. H GSEA analysis of HER2+-BC
patients data (TCGA-BRCA dataset) showing significant enrichment
of the “HALLMARK_UNFOLDED_PROTEIN_RESPONSE” gene
signature in USP22low tumors (USP22low: FPKM value≤29.56,
USP22high: FPKM value ≥ 38.46). I–J PERK inhibition in HCC1954
cells (GSK2606414, 8 μΜ, 24 h) (I) inhibits the induction of ATF3 and
BCL10 upon USP22 knockdown (as assessed by RT-qPCR) and (J)
reverses the induction of apoptosis upon USP22 loss (as assessed by
western blot for cleaved PARP). K–L PERK inhibition (GSK2606414,
8 μΜ) rescues the proliferation of HCC1954 (K) and SKBR3 cells (L)
upon siRNA mediated knockdown of USP22. Left panels: repre-
sentative crystal violet staining, right panels: quantification, respec-
tively. Statistical analyses: Student t-test (B), One-way Anova (I–L).
*p val < 0.05, **p val < 0.01. All experiments were performed in
biological triplicates or more (specified where applicable). Error bars:
standard error of the mean (SEM). NES Normalized
Enrichment Score.
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As described above, PERK plays a central role in the
activation of the UPR. Based on our findings that both
p-eIF2A and ATF4 levels were increased upon USP22
loss, together with an enrichment of a PERK-mediated
UPR gene expression signature in both in vivo and in vitro
models, we postulated that USP22 might suppress PERK
activation to maintain low UPR levels in cancer cells. To
test this hypothesis, we depleted USP22 in HCC1954 and
SKBR3 cells and examined the effects of treatment with
the PERK inhibitor (PERKi) GSK2606414. Strikingly,
PERK inhibition not only reversed the activation of UPR-
responsive genes (Fig. 4I, Fig. S3C) but also efficiently
rescued apoptosis-associated PARP cleavage caused by
UPS22 depletion (Fig. 4J) and cell viability of both cell
lines (Fig. 4K–L). To confirm that activation of the UPR
downstream of PERK impairs HER2+-BC cell growth,
we treated HCC1954 cells with the PERK activator
CCT020312 (2.5 μΜ) alone or in combination with USP22
knockdown. Indeed, PERK activation alone markedly
reduced HCC1954 proliferation and significantly poten-
tiated the anti-proliferative effects of USP22 depletion
(Fig. S3D). Taken together, our findings demonstrate that
USP22 supports the tumorigenic phenotype and reduces
the apoptotic rate of HER2+-BC cells by maintaining low
UPR-signaling.
USP22 suppresses UPR-induced apoptosis in HER2
+-BC by stabilizing HSPA5
In addition to its function in epigenetic regulation, USP22
has been shown to deubiquitinate several other cellular
proteins. Notably, a recent ubiquitinome-wide analysis
identified the heat shock 70 kDa protein 5 (HSPA5, also
known as BiP or GRP78) as a target of USP22-mediated
deubiquitination in prostate cancer cells [16]. Given the fact
that HSPA5 is a major regulator of PERK activity, we
hypothesized that USP22 may function to suppress UPR
activation by deubiquitinating and stabilizing this ER-
residing chaperone. To test this, we first examined the
impact of USP22 loss on the RNA and protein levels of
HSPA5 in the murine and human HER2+-BC models.
Consistent with our hypothesis, USP22-silencing specifi-
cally affected HSPA5 protein levels without affecting
HSPA5 mRNA expression in both human HER2+-BC cell
lines (Fig. 5A, B). Similarly, although Usp22fl/fl tumors
exhibit a significant increase in Hspa5 gene expression
compared to wild-type tumors, immunohistochemistry
staining showed a strong decrease in HSPA5 protein levels
(Fig. 5C, D and S4A). A direct stabilization of HSPA5 by
USP22-mediated deubiquitination suggests that these two
factors likely colocalize in the ER. While USP22 has been
reported to localize to the nucleus, its presence in the ER
compartment has not been reported to our knowledge.
Therefore, we performed immunostaining for USP22 and
examined its localization to the ER by confocal microscopy
and, indeed, confirmed its presence in the ER as assessed by
labeling with the ER-specific dye Cytopainter (Abcam)
(Fig. 5E). The specificity of the USP22-immunostaining
was validated through siRNA mediated silencing (Fig. 5E)
and loss of co-localizing signal in the ER and nucleus was
quantified (Fig. 5E right panel and S4B). To further confirm
that USP22 directly regulates HSPA5, we performed co-
immunoprecipitation to examine whether USP22 and
HSPA5 physically interact in cells. Indeed, immunopreci-
pitation of USP22 resulted in the co-precipitation of HSPA5
(Fig. 5F). Importantly, treatment of HCC1954 cells with the
proteasome inhibitor bortezomib restored HSPA5 levels
following USP22 depletion, further confirming a central
role of USP22 in stabilizing HSPA5 by preventing its
degradation by the ubiquitin-proteasome system (Fig. 5G).
Consistently, cycloheximide chase analyses demonstrated
that HSPA5 stability was significantly shorter upon USP22
loss compared to control transfected cells (Fig. 5H). Taken
together, these results demonstrate a previously unknown
role of USP22 in stabilizing HSPA5 in HER2+-BC.
HER2+-BC patients with HSPA5high-expressing lesions
have a poor survival outcome compared to their HSPA5low
counterparts (Fig. S4C). We, therefore, tested whether the
impairment of HSPA5 activity could phenocopy the loss of
USP22 and induce the UPR. Indeed, inhibition of HSPA5
using the specific inhibitor HA15 led to a pronounced
activation of UPR signaling as measured by the induction of
ATF3, PPP1R15A, DDIT3, BCL10, and CREB5 gene
expression in HCC1954 and SKBR3 cells (Fig. 5I and
S4D). Furthermore, HA15 treatment also increased the
apoptosis rate of HCC1954 cells (Fig. 5J). Consistently,
either HSPA5 inhibition or depletion significantly reduced
HER2+-BC cell viability (Fig. 5K and S4E) and these
effects could be potentiated by USP22 depletion (Fig. 5L
and S4F). Together, our study reveals a previously
unknown role of USP22 in suppressing the activation of
UPR signaling by stabilizing the major ER-resident mole-
cular chaperone HSPA5. Our results further reveal a vul-
nerability of HER2+-BC cells expressing low levels of
USP22 to UPR induction. This may provide a novel ther-
apeutic approach for innovative HER2+-BC treatment
strategies based on USP22 expression and/or inhibition.
Discussion
Because of its reported association with tumor aggressive-
ness and progression of numerous cancers, USP22 has been
the focus of increasing research efforts in recent years. As a
subunit of the SAGA complex, the epigenetic function of
USP22 via the deubiquitination of histone proteins has been
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extensively studied [24, 25, 39–42]. However, as observed
here and in previous studies, USP22 loss frequently does
not result in significant changes to global H2Bub1 levels,
suggesting USP22 enact non-epigenetic oncogenic func-
tions as well [23, 42]. Consistently, an increasing number of
studies have uncovered novel deubiquitination targets of
USP22 [10–18, 20–22]. In this way, USP22 can positively
influence numerous oncogenic signaling cascades. For
example, USP22 can promote breast cancer aggressiveness
by stabilizing the proto-oncogene c-Myc [10] to reprogram
cellular metabolism and stimulate mRNA and protein
synthesis [43]. Similarly, USP22 was also shown to pro-
mote hepatocellular cancer cell chemotherapy resistance,
nasopharyngeal carcinoma progression, and gastric cancer
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tumorigenic properties by stimulating the PI3K/AKT- and
the MAPK-signaling [44–46]. Noticeably, both of these
pathways also strongly positively influence metabolism, cell
growth, and protein synthesis by inducing the activity of
mTOR [47]. In contrast, both AKT and MAPK signaling
were unaffected in HER2+-BC in our study. Therefore, it
appears that USP22 oncogenic functions are context-
dependent, but frequently converge on the stimulation of
anabolic pathways that have been associated with an
increased ER stress load, including increased global protein
synthesis, which requires increased capacity for protein
folding [27, 43]. In this context, the UPR-signaling can act
as a negative feedback loop by inhibiting cap-dependent
translation to restore protein homeostasis and protect
against irreversible ER damage. However, how tumor cells
avoid excessive UPR activation and downstream activation
of p53-independent programmed cell death remains insuf-
ficiently understood.
To date, investigations into the function of USP22 in
breast cancer have been solely limited to in vitro studies and
immunohistochemical staining of tumor samples and did
not specifically investigate its relevance in HER2+-BC
[10, 18, 48]. In this study, we leveraged a previously
uncharacterized genetic mouse model, human cell lines, and
multiple publically available patient datasets to decipher the
role of USP22 in HER2+-BC. Consistent with previous
work in other breast cancer cell lines, loss of USP22 dra-
matically impaired tumorigenicity of HER2-driven mam-
mary carcinoma cells both in vivo and in vitro.
Interestingly, these effects were not related to a disruption
of the oncogenic HER2 signaling.
We recently reported a SAGA-related role for USP22 in
supporting the protein chaperoning system by tran-
scriptionally activating the expression of members of the
HSP90 family in colorectal and breast cancer cells [25]. In
this study, we identified a novel function of USP22 sup-
porting the protein chaperoning system by stabilizing the
major ER-resident chaperone protein HSPA5. HSPA5
belongs to the glucose-regulated protein family promoting
folding capacity and preventing the activation of stress sensor
receptors in the ER [49, 50]. Concordantly, pronounced
tumor supportive properties were described for HSPA5 in
different cancer entities including BC in vivo and in vitro
[49, 51, 52]. We observed that impaired expression of
USP22 sensitizes HER2+-BC to the programmed cell death
along the HSPA5/PERK/ATF4/ATF3-axis of the UPR (Fig.
6). Interestingly, numerous recent studies reported a vulner-
ability of HER2+-BC to ER stress induction, suggesting this
approach as an attractive alternative to specifically target this
type of malignancies [26, 28, 30]. Our work supports this
notion and describes an important implication of HSPA5 in
maintaining moderate UPR-signaling levels in USP22high
lesions. We, therefore, hypothesize that patients with
USP22high tumors may particularly benefit from therapies
specifically stimulating the activity of this pathway, possibly
in combination with inhibitors of USP22 activity. Recent
efforts have been made to design potent HSPA5-specific
small molecule inhibitors [53–57]. The small-molecule inhi-
bitor HA15, a thiazole benzenesulfonamide that specifically
inhibits HSPA5 ATPase activity, was shown to activate the
UPR-signaling in melanoma by disrupting its interaction with
PERK, IRE1, and ATF6 and demonstrated to overcome
BRAF therapy resistance of the cancer cells in vitro as well as
in xenograft analyses [58]. Our investigations further
demonstrated that the anti-tumor properties of HSPA5 inhi-
bition as well as small molecule-mediated PERK activation
may also apply to the HER2+-BC. Interestingly, the toxicity
of HSPA5 inhibitors seems to be restricted to cancer cells as
the tested compounds were well tolerated in murine xenograft
models [59].
Besides regulating the UPR, the identification of USP22-
enzymatic activity in the ER may have further consequences
for tumor cell aggressiveness. For instance, several groups
recently reported an important role of USP22 in stabilizing
Fig. 5 USP22 maintains HSPA5 stability and suppresses UPR-
induced apoptosis in HER2+-BC. A–B RT-qPCR (A) and western
blot analysis (B) assessing HSPA5 mRNA and protein levels in
siControl- and siUSP22-treated HCC1954 and SKBR3 cells, respec-
tively. C–D RT-qPCR (C) and immunohistochemical detection (D)
assessing HSPA5 mRNA and protein levels in Usp22wt/wt and Usp22fl/fl
tumors, respectively (n= 5 tumors per group). E A fraction of USP22
localizes in the ER, as assessed by confocal microscopy of co-stained
siControl and siUSP22 transfected HCC1954 cells (scale bar= 4 µm).
Left panel: representative pictures and co-localization signal (coloc);
right panel: quantification of the USP22 signal in the ER upon USP22
depletion (n= 19) compared to the controls (n= 27). F Co-
immunoprecipitation analysis of USP22 and HSPA5 in HCC1954
cells. IP immunoprecipitation. IB immunoblot. G Proteasome inhibi-
tion (bortezomib, 20 nM, 12 h) rescues loss of HSPA5 protein levels
upon USP22 knockdown in HCC1954 cells, as assessed by western
blot. H Cycloheximide chase assay (50 μΜ) showing a reduction of
HSPA5 protein stability upon USP22 knockdown in HCC1954 cells.
Left panel: representative HSPA5 western blot; right panel: densito-
metric quantification of HSPA5 protein levels over time and normal-
ized to the respective actin signal. Statistical tests on the last time
point. I RT-qPCR showing an expression increase of UPR responsive
genes (ATF3, PPP1R15A, and DDIT3) upon treatment of HCC1954
and SKBR3 cells with HA15 (20 μΜ, 24 h). J HCC1954 cells treated
with 20 µM HA15 for 48 h showed increased levels of the apoptosis
marker cl-PARP, as assessed by western blot. K Proliferation assay:
treatment of HCC1954 and SKBR3 cells with HA15 (32 μΜ and
10 μΜ, respectively) dramatically reduce their proliferation potential.
Left panels: representative pictures of crystal violet-staining; Right
panels: quantification of the respective confluency. L Assessment of
the growth kinetics of HCC1954 cells treated with siUSP22 and/or
HA15 (32 μΜ): quantification of the confluence (normalized to day 0)
over time by Celigo® measurements. Statistical tests were performed at
the last time point. Statistical test: Student t-tests (A, C, H, I, and K);
one-way Anova test (L); Mann–Whitney test (E) *p val < 0.05, ***p
val < 0.005, ns= not significant. All experiments were performed in
biological triplicates or more (specified where applicable). Error bars:
standard error of the mean (SEM).
USP22 promotes HER2-driven mammary carcinoma aggressiveness by suppressing the unfolded protein response 4013
PD-L1 and thereby helping tumor cells to escape immune
surveillance [22, 60]. As a plasma membrane protein, newly
synthesized PD-L1 is processed in the ER where it under-
goes post-translational modifications like glycosylation, but
also potentially poly-ubiquitination through the ER-resident
E3-ligase HRD1, thereby leading to ER-associated protein
degradation (ERAD) [61]. Similarly, Sonic Hedgehog
(SHH) is actively processed in the ER and the Golgi-
apparatus before secretion. SHH is a client of HRD1 for
ERAD-targeting [62]. Interestingly, it was also shown that
SHH undergoes USP22-mediated de-ubiquitination [19]. It
is therefore attractive to speculate that the stabilizing
function USP22 on PD-L1, SHH, and other factors may
actually take place, at least in part, in the ER.
Collectively, our present work identifies a new pro-
tumorigenic function of USP22 in the suppression of the
UPR-signaling, revealing its global role in supporting the
cellular protein chaperoning system and protecting tumor
cells against proteostasis imbalance. It is therefore tempting
to hypothesize that inhibition of USP22 activity could
represent an innovative approach to target HER2+-BC and
that simultaneous pharmacologic stimulation of UPR-
signaling could potentiate these effects.
Materials and Methods
Animal handling and mouse model generation
Animals were housed under specific pathogen-free (SPF)
conditions and in accordance with the animal welfare laws
and regulations of the state of Lower-Saxony (LAVES,
registration number #15/1754). For more details, please
refer to the Supplementary Data.
Publically available datasets
Publically available data were extracted from the Kaplan-
Meier plotter [63] (kmplot.com) and The Cancer Genome
Atlas (TCGA, xenabrowser.net) platforms to examine the
association of USP22 and HSPA5 expression with the
progression-free interval (PFI), relapse-free survival (RFS)
and distant metastasis-free survival (DMFS). Additionally,
overall survival (OS) of HER2+-BC patients was assessed
along with the expression of UPR-responsive genes. Please
refer to the Supplementary Data for BC subtype classifica-
tion parameters. Correlation of USP22 expression and UPR-
responsive genes was performed on the “Tumor Breast
(HER2)-Concha-66-fRMA-u133p2” dataset retrieved from
the online R2-platform (https://r2.amc.nl).
Cell culture, transfections, and functional assays
HCC1954 (ATCC® CRL-2338™) and SKBR3 (ATCC®
HTB-30™) cells were purchased from the American Type
Culture Collection (ATCC) and cultivated in RPMI 1640
GlutaMAX (Gibco) and DMEM/F12 GlutaMAX (Gibco)
supplemented with fetal bovine serum (Sigma-Aldrich) and
1x penicillin/streptavidin (Gibco), respectively (for more
details about the used cell lines, please refer to Table S1).
siRNA transfections were performed using Lipofectamine®
RNAiMAX (Invitrogen) in OptiMEM GlutaMAX (Gibco)
Fig. 6 USP22 promotes HER2-driven mammary carcinoma
aggressiveness by stabilizing HSPA5 and inhibiting the unfolded
protein response. A When highly expressed, USP22 stabilizes
HSPA5 via its deubiquitinase activity, increasing thereby the protein
folding capacity in the ER of cancer cells and maintaining low levels
of UPR signaling. B At low USP22 levels or upon USP22 impairment,
HSPA5 protein stability is decreased. As a consequence, unfolded
proteins accumulate in the ER, leading to the stimulation of the UPR.
Homodimerisation and autophosphorylation of PERK lead to the
phosphorylation of eIF2a (p-eIF2a), inhibiting the cap-dependent
translation and stimulating the synthesis of the ATF4 transcription
factor that in turn activates the expression of important effectors of the
UPR like ATF3. Prolonged activation of the PERK/ATF4/ATF3 axis
robustly induces the programmed cell death in a p53-independent
manner. Although no USP22-specific inhibitors are to date existing,
several HSPA5-specific inhibitors (e.g., HA15) or the PERK activator
CCT020312 have been developed. These inhibitors could help to
simulate a USP22low/null state in the tumor cells and substantially
contribute to the development of new UPR-based anti-cancer ther-
apeutic strategies.
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according to the manufacturer’s guidelines. A list of the
siRNAs utilized in this study is provided in Table S2.
Proliferation kinetics and tumorsphere numbers were
recorded using a Celigo® S imaging cytometer (Nexcelom
Bioscience LLC) or an IncuCyte® Live Cell Analysis Sys-
tem (Sartorius AG). Colony formation and trans-well
migration assays were stained with crystal violet and
scanned with an Epson Perfection V700 Photo. Detailed
protocols for siRNA transfection and functional assays can




Cells were reverse-transfected with siRNAs in 6-well plates
with coverslips and grown for another 72 h. Cells were then
washed with PBS, cross-linked with 4% paraformaldehyde
in PBS, and permeabilized with 0.4% (for ER staining;
Fig. 5E) or 1% Triton X-100 (for PCNA staining, Fig. 2G)
in PBS for 10 min. Subsequently, coverslips were blocked
for 1 h and incubated with the primary antibody overnight.
Coverslips were washed and a secondary antibody was
applied with DAPI for 1 h at room temperature. ER struc-
tures were stained using the Cytopainter dye (Abcam, ab-
1039482) according to the manufacturer’s instructions.
Coverslips were washed and mounted on microscope slides.
The detailed protocol as well the list of antibodies used in
this study are provided in the supplementary methods and
Table S3–4, respectively.
Immunohistochemistry
A detailed protocol is provided in the supplementary
methods. Briefly, 5 µm tissue sections were de-paraffinized
in xylene and rehydrated using decreasing alcohol con-
centrations. Antigen retrieval and endogenous peroxidase
block were performed in citric acid buffer (10 mM citric
acid, pH 6, 0.1% Tween 20) and 3% H2O2 in PBS,
respectively. Samples were then incubated in blocking
solution (5% bovine serum albumin (BSA, Merk) and 1%
donkey serum (Dianova GmbH) in PBS). Primary and
secondary antibodies (see supplementary Table S3-4) were
diluted in blocking solution and incubated in a dark humi-
dified chamber. Biotinylated secondary antibodies (GE
Healthcare, see supplementary Table S4) and ExtrAvidin-
Peroxidase (Sigma-Aldrich) were diluted in PBS, and sam-
ples were incubated in a dark humid chamber. Staining was
developed using 3,3′-diaminobenzidine-tetrahydrochloride
(DAB; Roth) and counterstained using hematoxylin. Slides
were dehydrated following the reverse order of the alcohol
gradient and mounted with Histokitt (Carl Roth GmbH).
Microscopy
Immunohistochemistry (IHC) pictures were taken with a
Zeiss Axio Scope A1. Brightfield images of cultured cells
were taken with a Nikon Eclipse S100 inverted microscope




Seventy-two hours post transfection, adherent, and floating
cells were collected, washed twice with PBS, and resus-
pended in binding buffer (10mM HEPES, pH 7.4; 140 mM
NaCl; 25 mM CaCl2) at a concentration of 10
5 cells in 100 µl.
5 µl Annexin V-FITC (Southern Biotech) and 1 µl propidium
iodide (Sigma Aldrich) were added per sample, gently mixed,
and incubated for 15 min at room temperature in the dark.
400 µl binding buffer was subsequently added to each sample.
Analysis of the Annexin V staining was performed using a
Guava EasyCyte Plus flow cytometer (Guava Technologies).
Protein stability assessment
Cycloheximide chase assay
siControl- and siUSP22-transfected HCC1954 cells were
treated with 50 μΜ of cycloheximide (Sigma) at different
time points (64, 66, 68, and 70 h post-transfection) to
achieve 8, 6, 4, and 2 h treatment, respectively. The
experiment was stopped at 72 h post transfection and pro-
teins were harvested for later analysis via western blot.
Proteasome inhibition assay
60 h post-transfection, siControl- as well as siUSP22-
transfected HCC1954 cells were treated with 20 nM borte-
zomib (Selleckchem) for 12 h. Control cells were treated
with DMSO as a vehicle in all experiments. The experiment
was stopped at 72 h post-transfection and proteins were
harvested for later analysis via western blot.
Co-immunoprecipitation (CoIP) assay
CoIP was performed based on Wienken et al. [64]. A
detailed procedure is provided in the Supplementary Data.
RNA isolation and real-time quantitative PCR
(RT-qPCR)
RNA isolation, cDNA synthesis, and RT-qPCR were per-
formed as previously described [65, 66]. Detailed protocols
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are provided in Supplementary Data. The sequences of
primers used in this study are provided in Table S5.
mRNA library preparation and data analysis
mRNA sequencing (mRNA-seq) libraries were generated
from MMTV-Erbb2 tumors with the TruSeq® RNA
Library Prep Kit v2 (Illumina) according to the manu-
facturer’s instructions and samples were sequenced (sin-
gle-end 50 bp) on a HiSeq4000 (Illumina) at the NGS
Integrative Genomics Core Unit (NIG) of the University
Medical Center Göttingen (UMG). mRNA-seq data were
then processed and analyzed in the Galaxy environment
provided by the “Gesellschaft für Wissenschaftliche
Datenverarbeitung mbH Göttingen” (GWDG). Briefly, the
first 11 nucleotides of the raw reads were trimmed
(FASTQ Trimmer). Murine mRNA-seq data were mapped
to the mm10 reference genome using RNA STAR (version
2.4.0d-2), and human mRNA-seq data were aligned to the
hg19 reference genome using the TopHat Gapped-read
mapper (version 2.1.1) [67, 68]. Read counts per gene
were calculated with featureCounts (version 1.4.6.p5).
Finally, differential gene expression analysis and normal-
ized counts were obtained using DESeq2 (version 2.11.39)
[69]. To identify differentially regulated genes upon
USP22 loss, we used a cut-off of |log2 fold change| ≥ 1;
FDR < 0.05 and |log2 fold change| ≥ 0.6, p value < 0.05
in murine tumors and HCC1954 cells, respectively. A
detailed analysis workflow is available in Supplementary
Data. Raw sequencing data are accessible at ArrayExpress
(https://www.ebi.ac.uk/arrayexpress/) with the following
accession number: E-MTAB-9331 (MMTV-Erbb2 mouse
model), E-MTAB-8256 (HCC1954).
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